Edward F. Fritsch

Last updated

Edward Francis Fritsch (born June 1, 1950) is a scientist in the field of molecular biology and cancer immunology. [1]

Fritsch completed his PhD at the University of Wisconsin–Madison under Howard Temin. [1] [2] His thesis was titled, "Synthesis and structure of avian retrovirus DNA". [1] As a postdoctoral fellow under Tom Maniatis at California Institute of Technology, Fritsch entered the field of recombinant DNA by constructing the first complete library of the human genome along with Dr. Richard Lawn. [3] [4] In 1982, Fritsch, Joe Sambrook, and Maniatis wrote Molecular Cloning: A Laboratory Manual, which was considered "omnipresent in Molecular Biology laboratories and [...] utilized to the point where it is frequently referred to as ‘The Bible’.” [5] Fritsch helped initiate and for four years co-taught the widely successful Cold Spring Harbor course on Molecular Cloning. [6] Fritsch's work in molecular cloning continued at Genetics Institute, acquired by Wyeth in 1992, where he worked on the discovery and production of therapeutic recombinant proteins, including the cloning of the erythropoietin (EPO) gene. [7]

Fritsch then joined Phylos, Inc. to utilize a in vitro, directed-evolution technology to discover new protein therapeutics, eventually becoming Chief Scientific Officer [8]

He later worked with Cathy Wu and Nir Hacohen at the Dana–Farber Cancer Institute and the Broad Institute of MIT and Harvard. [9] There he led the development of NeoVax, a first-in-class personalized neoantigen cancer vaccine through IND approval and successful execution of two clinical trials [10] [11]

In 2015, he co-founded Neon Therapeutics, Inc. [12] (acquired by BioNTech in 2020 for $67M), [13] as Chief Technology Officer to work on personalizedcancer vaccines. [14] In 2019, he left Neon to re-join the Dana–Farber Cancer Institute and the Broad Institute to continue work on the subject.

References

  1. 1 2 3 "Synthesis and structure of avian retrovirus DNA". ProQuest. ProQuest. Retrieved 9 November 2023.
  2. ↑ "About us". UCIR. Understanding Cancer Immunotherapy Research. Retrieved 9 November 2023.
  3. ↑ Claiborn, Kathryn (2012-10-01). "Gene pioneers: Donald Brown and Thomas Maniatis win the 2012 Lasker~Koshland Special Achievement Award in Medical Science". The Journal of Clinical Investigation. 122 (10): 3383–3386. doi:10.1172/JCI66476. ISSN   0021-9738. PMC   3461937 . PMID   23193577.
  4. ↑ Lawn, Richard M.; Fritsch, Edward F.; Parker, Richard C.; Blake, Geoffrey; Maniatis, Tom (1978-12-01). "The isolation and characterization of linked δ- and β-globin genes from a cloned library of human DNA" . Cell. 15 (4): 1157–1174. doi:10.1016/0092-8674(78)90043-0. ISSN   0092-8674. PMID   728996. S2CID   54279445.
  5. ↑ "Molecular Cloning (AKA Maniatis, AKA The Bible) at 25". Bench Marks. 2007-10-22. Retrieved 2020-08-19.
  6. ↑ Clark, Jess. "Recipes for Recombining DNA. A History of Molecular Cloning: A Laboratory Manual". The Recipes Project. Retrieved 2020-08-19.
  7. ↑ Jacobs, Kenneth; Shoemaker, Charles; Rudersdorf, Richard; Neill, Suzanne D.; Kaufman, Randal J.; Mufson, Allan; Seehra, Jasbir; Jones, Simon S.; Hewick, Rodney; Fritsch, Edward F.; Kawakita, Makoto (February 1985). "Isolation and characterization of genomic and cDNA clones of human erythropoietin" . Nature. 313 (6005): 806–810. Bibcode:1985Natur.313..806J. doi:10.1038/313806a0. ISSN   1476-4687. PMID   3838366. S2CID   4340224.
  8. ↑ Fritsch, Edward. "Protein Scaffolds for Novel Anti-Cancer Agents".{{cite journal}}: Cite journal requires |journal= (help)
  9. ↑ Hacohen, Nir; Fritsch, Edward F.; Carter, Todd A.; Lander, Eric S.; Wu, Catherine J. (2013-07-01). "Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines". Cancer Immunology Research. 1 (1): 11–15. doi:10.1158/2326-6066.CIR-13-0022. ISSN   2326-6066. PMC   4033902 . PMID   24777245.
  10. ↑ Ott, Patrick A.; Hu, Zhuting; et al. (July 2017). "An immunogenic personal neoantigen vaccine for patients with melanoma". Nature. 547 (7662): 217–221. Bibcode:2017Natur.547..217O. doi:10.1038/nature22991. ISSN   1476-4687. PMC   5577644 . PMID   28678778.
  11. ↑ Keskin, Derin B.; Anandappa, Annabelle J.; et al. (January 2019). "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial". Nature. 565 (7738): 234–239. doi:10.1038/s41586-018-0792-9. hdl: 1721.1/125401 . ISSN   1476-4687. PMC   6546179 . PMID   30568305. S2CID   216713646.
  12. ↑ "Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies". FiercePharma. Retrieved 2020-08-19.
  13. ↑ "BioNTech to acquire Neon to strengthen global leadership position in T cell therapies | BioNTech". investors.biontech.de. Retrieved 2020-08-19.
  14. ↑ "Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2017". BioSpace. Retrieved 2020-08-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.